Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Pulmonx (LUNG) Shares Outstanding (2019 - 2025)

Pulmonx has reported Shares Outstanding over the past 7 years, most recently at $41.7 million for Q4 2025.

  • Quarterly Shares Outstanding rose 4.74% to $41.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.7 million through Dec 2025, up 4.74% year-over-year, with the annual reading at $41.7 million for FY2025, 4.74% up from the prior year.
  • Shares Outstanding was $41.7 million for Q4 2025 at Pulmonx, up from $41.2 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $41.7 million in Q4 2025 and troughed at $35.8 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $38.2 million (2023), against an average of $38.5 million.
  • Year-over-year, Shares Outstanding surged 1635.08% in 2021 and then grew 1.6% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $36.9 million in 2021, then rose by 1.69% to $37.6 million in 2022, then grew by 2.56% to $38.5 million in 2023, then grew by 3.3% to $39.8 million in 2024, then grew by 4.74% to $41.7 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Shares Outstanding are $41.7 million (Q4 2025), $41.2 million (Q3 2025), and $40.7 million (Q2 2025).